Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16364413 | 0.88 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9ASMN1; SMN2PLA2G4B | |
| SCHEMBL12901277 | 0.87 | ALDH1A1 (0.43) | ALDH1A1NPC1RAB9ASMN1; SMN2PLA2G4B | |
| SCHEMBL1228697 | 0.87 | ACHE (0.40) | ALDH1A1SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL5316860 | 0.84 | ALDH1A1 (0.41) | ALDH1A1HTTPKMKMT2A | |
| SCHEMBL5540389 | 0.77 | ALDH1A1 (0.38) | ALDH1A1PKMKMT2A | |
| SCHEMBL28531344 | 0.76 | CHRM1 (0.47) | ALDH1A1GAAPKMKMT2A | |
| SCHEMBL28523272 | 0.76 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2LMNAPKMKMT2A | |
| SCHEMBL28523274 | 0.76 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2LMNAPKMKMT2A | |
| SCHEMBL5539609 | 0.76 | CHRM1 (0.47) | ALDH1A1GAAPKMKMT2A | |
| SCHEMBL12901280 | 0.76 | MAPT (0.38) | ALDH1A1NPC1RAB9APLA2G4BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293734-B2 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | NOX5, NQO2, SIRT5 | ALDH1A1 2444/4885NPC1 2519/4885RAB9A 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.